Navigation Links
GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
Date:6/16/2008

spectrum of bacterial susceptibility. I look forward to having a great synergy in this important and strategic collaboration."

Bacterial efflux pumps are an intrinsic defense mechanism in gram-negative bacteria that expel toxins such as antibiotics that have permeated the outer cell membrane before they can reach their targets and kill the bacteria. Higher intracellular antibiotic concentrations achieved through efflux pump inhibition can increase the potency and pharmacological barrier against other drug resistance mechanisms (e.g., target-based mutations). There are currently no drugs approved to inhibit the activity of these efflux pumps and restore the potency of otherwise effective antibiotics. Mpex has been a leader in this field of research for a number of years and has identified several series of lead EPIs that are now being optimized for development. These compounds have been shown in both in vitro and in vivo pre-clinical studies to significantly improve the potency of a number of different antibiotic classes against drug- resistant gram-negative pathogens, including Pseudomonas aeruginosa and Klebsiella pneumoniae.

About Mpex Pharmaceuticals

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance. Mpex's lead product candidate, MP-376, is a proprietary aerosol formulation of levofloxacin that is being developed clinically as a maintenance therapy for the prevention of bacterial exacerbations in patients with cystic fibrosis and severe chronic bronchitis. The company has also built a discovery and development platform and intellectual property estate arou
'/>"/>

SOURCE Mpex Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
2. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
3. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
4. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
5. Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline
6. Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline
7. Vaccinex Antibody Licensed to GlaxoSmithKline
8. GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
9. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
10. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
11. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 03, 2015 Becht Engineering Co., ... it has acquired The CECON Group, Inc., located ... were not announced. , Becht Engineering (http://www.becht.com ... sector including oil and gas production, refining, petrochemical, ... nuclear power sectors. The company has twelve offices ...
(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/s3s3t8/personalized ... new report "Personalized Medicine - Scientific and ... The aim of personalized medicine or ... to the right patient and, in some cases, ... patient according to his/her genotype. This report describes ...
(Date:3/3/2015)... 2015  Johnson & Johnson Innovation LLC today announced ... (JLABS @SSF), a 30,000-square foot incubator located ... Francisco, Calif. The Johnson & Johnson Innovation, ... from across the healthcare spectrum including biotech, pharmaceutical, medical ... first resident startups have been selected, including the winners ...
(Date:3/3/2015)... , March 3, 2015  Synthetic Biologics, Inc. (NYSE ... and diseases, with a focus on protecting the microbiome, announced ... scheduled to present at the 27th Annual ROTH Conference being ... Laguna Niguel in Dana Point, CA. ... March 10, 2015 at 1:00 p.m. (Pacific Time). ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
... Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today that ... Second Annual Hidden Gems Conference on October,13, 2008 at ... the,Waldorf=Astoria Hotel in New York City. Robert E. Hoffman, ... to provide an,overview of the company, including its clinical ...
... 7 Nektar,Therapeutics (Nasdaq: NKTR ) President and ... upcoming Natixis Bleichroeder Second Annual Hidden Gems,Conference in New ... at 2:30 p.m. ET., The presentation will be ... Relations, Events Calendar section of the Nektar website:, http://www.nektar.com ...
... 7 MKS Instruments, Inc.,(Nasdaq: MKSI ), ... and improve productivity, today announced that it will ... opening on Wednesday,October 22, 2008. A conference call ... 8:30 a.m. (Eastern Time). The call will be ...
Cached Biology Technology:Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 3
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/12/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... for DISTRIBUTED METHOD AND SYSTEM TO IMPROVE ... further establishes NXT-ID,s position in the emerging "Internet of ... ability for multiple devices to collaborate with one another ...
(Date:2/9/2015)... Texas , Feb. 9, 2015  Lintec of ... fabrication methods for carbon nanotube (CNT) macrostructures, including sheets, ... at Dallas (UTD). Leveraging the vast industrial ... Tokyo, Japan , Lintec of America is ... Richardson, TX , focusing on scaling up ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... researchers from the British Antarctic Survey have collected individuals from ... and subjected them to increasing levels of water temperature to ... conditions that they are likely to experience in the future. ... living really close to their upper temperature range, and that ...
... A University of Wisconsin-Madison biomedical engineer and colleagues have developed ... could spare some women with increased breast cancer risk the ... a questionable lump or lesion. The universal technology will ... malignant or benign. The American Cancer Society recommends ...
... an effort to increase understanding of the medical device ... of product development more effectively, researchers at Stanford University ... device development process. Published in the June ... , the model was constructed based on best-practice analysis ...
Cached Biology News:New MRI technique could mean fewer breast biopsies in high-risk women 2Stanford researchers publish comprehensive model for medical device development 2Stanford researchers publish comprehensive model for medical device development 3